Vernalis PLC' AUY922 Update

20 July 2011 -- Vernalis plc today announces that Novartis, at its Q2 results webcast, provided an update on the status of the Hsp90 inhibitor AUY922, which was discovered under collaboration with Novartis.

AUY922 is included for the first time in Novartis’ selected pharmaceutical pipeline projects chart.

More information can be found on Novartis’ website (www.novartis.com).

Enquiries:

Vernalis Contacts

Ian Garland, Chief Executive Officer +44 (0) 118 989 9360

David Mackney, Chief Financial Officer

Brunswick Group

Jon Coles +44 (0) 20 7404 5959

Justine McIlroy

Taylor Rafferty

Rob Newman +44 (0) 20 7614 2900

Faisal Kanth

About Vernalis

Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are the subject of collaborations with Endo, GSK, Lundbeck, Menarini, Novartis and Servier.

Back to news